The Orlando Health Heart Institute’s Pulmonary Hypertension Program was recently recognized as an accredited comprehensive care center through the Pulmonary Hypertension Association (PHA)’s accreditation program for Pulmonary Hypertension Care Centers (PHCCs). Qualifying PHCCs are either designated as a PHA-accredited Center of Comprehensive Care (CCC) or PHA-accredited Regional Clinical Program (RCP) based on…
Don Stevenson, also known as the Pacing Parson, is marking his 80th birthday with a 1,000-mile benefit and awareness walk for the Pulmonary Hypertension Association (PHA), a nonprofit group dedicated to extending and improving the lives of those affected by pulmonary hypertension (PH). The PHA is asking the public to support Stevenson in his efforts.
The Pulmonary Hypertension Association (PHA) recently announced the three pulmonary hypertension (PH) researchers chosen to receive its 2015 Robyn Barst Pediatric PH Research and Mentoring Awards. According to a press release, the three $50,000 award winners, whose work will also be mentored for a year, are: David Brian…
The Pulmonary Hypertension Association (PHA) announced that three more centers recently received Pulmonary Hypertension Care Center (PHCC) accreditation, raising the total number of PHA-accredited clinics to 32 across the U.S. In addition to acknowledging a high level of patient care, accreditation allows these centers to contribute to the Pulmonary Hypertension Association Registry…
Actelion Pharmaceuticals, Ltd., recently announced that the selective IP receptor agonist Uptravi (selexipag) has been granted Notice of Compliance (NOC) approval by Health Canada for the treatment of pulmonary arterial hypertension (PAH). Uptravi (selexipag) was originally discovered and synthesized by Nippon Shinyaku as an oral, prostacyclin receptor agonist formulated…
The phaware global association knows the soon-to-be-played Super Bowl 50 will attract plenty of fans and attention — and it’s teaming with the biggest sporting event in the U.S. (and a popular one elsewhere) to kick off its 2016 pulmonary hypertension global awareness campaign — Engage for a Cure — with the BIG GAME…
Work on a doctoral dissertation at Umeå University in Sweden led to the discovery of new blood biomarkers reflecting vasoreactivity in lung blood vessels of patients with heart and lung disease, which can lead to simplified diagnostics and better treatment evaluation in patients with pulmonary arterial hypertension (PAH). L-arginine and dimethylarginines, the…
Morphogen-IX, a new biotechnology company based in Cambridge, United Kingdom, has received financial support to potentially advance a new treatment for pulmonary arterial hypertension (PAH) that targets the main pathway involved in the disease. The treatment may provide the first disease-modifying drug for the condition, and is based on fifteen years of research by…
The Pulmonary Hypertension Association (PHA) is celebrating its 25th birthday in 2016 by highlighting major Pulmonary Hypertension treatment advances made over the past two decades, in order to encourage those with PH to remain hopeful for the development of future therapeutic advancements that will improve quality of life and lifespan. To mark the occasion, the association…
A new study is investigating whether tocilizumab, an immunosuppressive drug mainly used as a therapy for rheumatoid arthritis and systemic juvenile idiopathic arthritis, might also be a treatment for pulmonary arterial hypertension (PAH). Treatment options now available for the condition only alleviate disease symptoms. Tocilizumab may become the first disease modifying PAH drug. The…
The legendary singer Natalie Cole, the daughter of Nat King Cole, died on New Year’s Eve at the Cedars-Sinai Hospital in Los Angeles of idiopathic pulmonary arterial hypertension (IPAH), which led to heart failure, according to a statement released by her family. She was 65. Cole had battled health issues for years,…
Data from a Phase 3 clinical trial showed that patients with pulmonary arterial hypertension (PAH) might benefit from selexipag treatment, as the drug was seen to lower the risk of death or PAH-related complications. The study, published in the New England Journal of Medicine, is titled “Selexipag for the…
Get regular updates to your inbox.